Trials / Not Yet Recruiting
Not Yet RecruitingNCT04351282
SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 43 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Primary metastatic NPC patients received chemotherapy± immunotherapy, radiation for primary tumors and SBRT for metastatic lesions.
Detailed description
The eligible patients will receive 4-6 cycles chemotherapy±immunotherapy and radical radiotherapy for nasopharyngeal tumors. Then, SBRT for oligometastatic lesions will be assigned to eligible patients. The efficacy and side-effect will be evaluated and analyzed. The relation of liquid biopsy data with treatment outcome（such as EBV DNA, CTCs, CTC subtype，PD-L1 and so on）will be valued.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | SBRT | SBRT for oligometastatic lesions will be assigned to those who got PR,SD after systemic treatment. |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2026-05-31
- Completion
- 2026-05-31
- First posted
- 2020-04-17
- Last updated
- 2020-04-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04351282. Inclusion in this directory is not an endorsement.